↑ 疾患リストへ ← 戻る

 201. アンジェルマン症候群 [臨床試験数:12,薬物数:15(DrugBank:7),標的遺伝子数:22,標的パスウェイ数:20] 

Searched query = "Angelman syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04106557September 9, 201914 October 2019A Study of OV101 in Individuals With Angelman Syndrome (AS)A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman SyndromePrimary Disease or Condition Being Studied: Angelman Syndrome (AS)Drug: Gaboxadol;Drug: PlaceboOvid Therapeutics Inc.Recruiting2 Years12 YearsAll65Phase 3United States
2NCT03882918February 25, 20198 April 2019An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromeAn Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromeAngelman SyndromeDrug: OV101Ovid Therapeutics Inc.Recruiting13 Years49 YearsAll82Phase 2United States
3NCT03644693August 13, 20183 September 2018Nutritional Formulation for Angelman SyndromeEvaluation of the Safety and Tolerability of a Nutritional Formulation in Angelman SyndromeAngelman SyndromeDietary Supplement: Nutritional Formulation Containing Exogenous Ketones;Dietary Supplement: Placebo FormulationVanderbilt University Medical CenterRecruiting4 Years11 YearsAll15N/AUnited States
4NCT03109756April 3, 201716 December 2017Single Dose Pharmacokinetic (PK) StudyA Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman SyndromeAngelman Syndrome;Fragile X SyndromeDrug: OV101Ovid Therapeutics Inc.Not recruiting13 Years17 YearsAll12Phase 1United States
5NCT02996305January 201620 August 2018A Study in Adults and Adolescents With Angelman SyndromeA Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of GaboxadolAngelman SyndromeDrug: OV101 Regimen 1;Drug: OV101 regimen 2;Other: PlaceboOvid Therapeutics Inc.Not recruiting13 Years49 YearsAll88Phase 2United States;Israel
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02056665January 20142 November 2015Study to Evaluate the Efficacy and Safety of Minocycline in Angelman SyndromeRandomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman SyndromeAngelman SyndromeDrug: MINOCYCLINE;Drug: PLACEBO (for Minocycline)Puerta de Hierro University HospitalNot recruiting6 Years30 YearsBoth32Phase 2Spain
7EUCTR2013-002154-67-ES26/12/201327 January 2014STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) - A-MANECEAngelman Syndrome
MedDRA version: 16.0 Level: PT Classification code 10049004 Term: Angelman's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Aknemin 50
Pharmaceutical Form: Capsule
INN or Proposed INN: MINOCYCLINE
CAS Number: 13614-98-7
Current Sponsor code: PL 33016/0005
Other descriptive name: MINOCYCLINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Dra. Cristina Avendaño SoláAuthorisedFemale: yes
Male: yes
Spain
8NCT03235037November 26, 201329 April 2019Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man SyndromeClinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man SyndromeAngelman SyndromeDrug: LevodopaBennett LavensteinNot recruiting18 Months16 YearsAll10N/A
9NCT01531582April 201219 February 2015Minocycline in the Treatment of Angelman SyndromeThe Efficacy of Minocycline in the Treatment of Angelman SyndromeAngelman SyndromeDrug: minocyclineUniversity of South FloridaNot recruiting4 Years12 YearsBoth25N/AUnited States
10NCT01281475January 201119 October 2017A Trial of Levodopa in Angelman SyndromeA Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman SyndromeAngelman SyndromeDrug: Placebo Oral Capsule;Drug: LevodopaWen-Hann TanRady Children's Hospital, San Diego;University of California, San Francisco;Baylor College of Medicine;Vanderbilt University;Greenwood Genetic Center;Children's Hospital Medical Center, Cincinnati;Angelman Syndrome Foundation, Inc.Not recruiting4 Years12 YearsAll67Phase 2/Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00829439January 200919 October 2017Study on Tolerability of Levodopa/Carbidopa in Children With Angelman SyndromeA Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman SyndromeAngelman SyndromeDrug: Levodopa/Carbidopa (4:1)Boston Children’s HospitalNot recruiting4 Years12 YearsAll16Phase 1United States
12NCT00348933July 200619 October 2017Dietary Supplements for the Treatment of Angelman SyndromeEfficacy of a Therapeutic Treatment Trial in Angelman SyndromeAngelman Syndrome;Nervous System DiseasesDrug: Betaine;Drug: Creatine;Drug: Metafolin;Drug: Vitamin B12University of California, San DiegoBaylor College of Medicine;Rady Children's Hospital, San Diego;Boston Children’s Hospital;Greenwood Genetic Center;Rare Diseases Clinical Research NetworkNot recruitingN/A5 YearsAll90N/AUnited States

先頭へ